Related coverage linked through entity extraction aliases.
Mar 18, 2026
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
Mar 18, 2026
Mayo Clinic is pursuing two distinct nanoparticle-based cancer treatments: milk-derived nanoparticles for targeted gene therapy in bile duct cancer, and magnetic nanoparticle hyperthermia for metastatic solid tumors.
Mar 17, 2026
A redesigned CD40 agonist antibody achieved complete remission in two of 12 patients with metastatic cancer in early trials, while separate research identified a method to prevent deadly heart complications from immune checkpoint inhibitors.
Mar 17, 2026
Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.
Mar 14, 2026
The ASCENT-04 trial showed sacituzumab govitecan plus pembrolizumab improved progression-free survival in PD-L1-positive TNBC without increased toxicity. Meanwhile, experts debate whether ADCs function as targeted therapy or advanced chemotherapy, with sequencing questions remaining unresolved.
Mar 14, 2026
A University of Houston researcher has joined a $3.2 million effort to develop a new drug targeting MDM2, a cancer-driving protein in triple-negative breast cancer. The compound has shown ability to shrink tumors in early laboratory models.
Mar 12, 2026
Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.
Mar 13, 2026
Recent studies examine self-management strategies for breast cancer treatment-related cardiotoxicity and highlight risks of vertebral fractures after discontinuing denosumab therapy in patients receiving aromatase inhibitors.
Mar 13, 2026
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
Mar 11, 2026
Exploratory analysis from a phase 1/2 trial shows CD47 expression levels predict response to evorpacept plus zanidatamab in heavily pretreated HER2-positive metastatic breast cancer patients, supporting biomarker-driven patient selection.
Mar 11, 2026
New technologies combining patient-derived organoid models with artificial intelligence are enabling researchers to predict treatment responses and monitor tumor behavior in ways that could advance personalized cancer care.
Mar 10, 2026
Roche's experimental breast cancer pill giredestrant combined with a CDK4/6 inhibitor failed to meet its primary endpoint in a Phase III trial for first-line treatment of ER-positive, HER2-negative advanced breast cancer, marking a setback for the drugmaker's next-generation hormone therapy program.
Mar 10, 2026
The US FDA granted priority review and the European Medicines Agency validated applications for Enhertu as post-neoadjuvant treatment for HER2-positive early breast cancer, based on Phase III trial data showing 53% reduction in recurrence risk.
Mar 09, 2026
FDA elevated OS Therapies' Type D meeting to Type B pre-BLA meeting for OST-HER2 in osteosarcoma, signaling transition to Accelerated Approval discussions. Clinical data submission targeted for end of Q1 2026.
Mar 08, 2026
New research shows genomic profiling can detect aggressive prostate cancer not identified at biopsy, while a separate study reveals PTGES3 as a potential therapeutic target for treatment-resistant disease.
Mar 06, 2026
New research examines both the long-term biological aging effects of childhood cancer treatments and proposes alternative treatment sequencing strategies to prevent tumor resistance and improve cure rates.
Mar 06, 2026
Roche announced positive phase II results for obesity drug petrelintide showing 10.7% weight reduction, while the FDA set a December 18 decision date for breast cancer drug giredestrant.
Mar 06, 2026
Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.
Mar 05, 2026
Whole genome sequencing, comprehensive genomic profiling, and spatial multiomics are transforming precision medicine from research tools to clinical applications in oncology, rare diseases, and neonatal care, enabling faster diagnoses and personalized treatments.
Mar 04, 2026
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
